Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
January 22nd 2025"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
January 22nd 2025"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
The economics of bladder cancer in the US: Increasing costs and unsustainable patterns
January 11th 2025"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.